Biomarkers of Cardiovascular Risk in Haemodialysis Patients

Title:Biomarkers of Cardiovascular Risk in Haemodialysis Patients

Volume: 23 Issue: 39

Author(s): Beata Franczyk, Anna Gluba-Brzozka*Jacek Rysz

Affiliation:

• Department of Nephrology, Hypertension and Family Medicine, WAM Teaching Hospital, Lodz,Poland

Keywords: Dialysis, GDF-15, copeptin, h-FABP, biomarker, HDL, LDL subfractions.

Abstract: Background: All stages of chronic kidney disease (CKD) are associated with increased risks of atherosclerosis and cardiovascular morbidity and mortality. According to studies, levels of copeptin, growth differentiation factor-15 (GDF-15) and heart fatty-acid binding protein (h-FABP) are increased in dialysis patients.

Materials: This study included 50 patients (19 women, 31 men) chronically undergoing haemodialysis. The concentration of markers such as: copeptin, GDF-15, h-FABP, troponin and serum creatine kinase MB (CKMB) was measured with the use of ELISA tests. Serum concentration of 10 high-density lipoprotein (HDL) subfractions and 7 low-density lipoprotein (LDL) subfractions was analysed with the use of Lipoprint™ system (Quantimetrix Corp.).

Results: In this study, we observed higher copeptin level, lower percentage share of cholesterol HDL4 subfraction and higher percentage share of small HDL particles subfraction in HD patients with diabetes mellitus than in those without diabetes. We also found significantly lower percentage share of cholesterol HDL5 subfraction in patients with GDF-15 > 3rd quartile (Q3) compared with those with GFD-15 ≤ Q3. Finally, it was observed that the percentage share of cholesterol HDL5 subfraction was significantly lower in patients with h-FABP > Q3, and the share of intermediate HDL subfractions was significantly lower in haemodialysis (HD) patients with h-FABP > 75 percentile.

Conclusion: The fact that increased level of one biomarker correlated with higher values of other markers may suggest that their concentration depends on the severity of disease. The obtained results also suggest that the measurement of copeptin may support the diagnosis of cardiovascular problems in dialysis patients.

Cite this article as:

Franczyk Beata, Gluba-Brzozka Anna *, Rysz Jacek, Biomarkers of Cardiovascular Risk in Haemodialysis Patients, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170816114816